Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human normal immunoglobulin (Kedrion Biopharma)
- Development stage
- Unknown
- Lead developer
- Kedrion
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Kedrion SCIg is a 16% subcutaneous human normal immunoglobulin (SCIg) preparation developed by Kedrion Biopharma for the treatment of primary and secondary immunodeficiency disorders. As a plasma-derived biologic, it consists of highly purified immunoglobulin G (IgG) antibodies harvested from human plasma pools. The therapy is designed to provide passive immunity by replacing deficient or absent endogenous IgG, thereby preventing recurrent bacterial and viral infections in patients with hypogammaglobulinaemia or agammaglobulinaemia. The 16% concentration allows for the administration of high doses in smaller volumes compared to lower-concentration formulations, facilitating subcutaneous delivery. It has been evaluated in Phase II/III clinical trials in Italy, demonstrating efficacy, safety, and tolerability as a replacement therapy.
- Other names
- Kedrion SCIg16% subcutaneous human normal immunoglobulinKedrion 16% SCIghuman normal immunoglobulin 16%
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on human normal immunoglobulin (Kedrion Biopharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human normal immunoglobulin (Kedrion Biopharma).